Innovation and Technology Adoption in Health Care Markets
Book Forum
About This Event

Almost all pharmaceuticals are purchased by third parties (insurance or government) through the use of reimbursements. Yet, as University of Chicago health economists Anupam B. Jena and Tomas J. Philipson demonstrate in their new book, Innovation and Technology Adoption in Health Care Markets (AEI Press, August 2008), reimbursement levels based Listen to Audio


Download Audio as MP3
on the cost-effectiveness of drugs--usually measured as the cost per quality-adjusted life-year saved by a drug--tend to sacrifice future drug development because they limit profits to be made and therefore discourage manufacturers from investing in useful innovation.

Based on the careful empirical analysis of drugs used to treat HIV/AIDS, Philipson and Jena conclude that drug manufacturers glean only about 5 percent of the mammoth returns brought about by these life-saving therapies. As a result, patients may be worse off than they would be with policies based less on cost-savings and more on incentives to develop new technologies. The implications of these findings, when taking account of other valuable drug classes, suggest that we face the prospect of paying less money for drugs now while getting far fewer new drug treatments later.

Joining the authors to discuss this important book will be pharmaceutical economist Christopher Adams from the Federal Trade Commission. AEI's John E. Calfee will moderate.

Agenda
2:45 p.m.
Registration
3:00
Presenters:
Anupam B. Jena, University of Chicago
Tomas J. Philipson, University of Chicago and AEI
Discussant:
Christopher Adams, Federal Trade Commission
Moderator:
5:00
Adjournment
Also Visit
AEIdeas Blog The American Magazine

What's new on AEI

To secure southern border, US must lead international effort to stabilize Central America
image The Ryan pro-work, anti-poverty plan: Thomas Aquinas 1, Ayn Rand 0
image Does SNAP support work? Yes and no
image Obama Democrats lose their big bet on health exchanges
AEI Participants

 

John E.
Calfee
  • Economist John E. Calfee (1941-2011) studied the pharmaceutical industry and the Food and Drug Administration (FDA), along with the economics of tobacco, tort liability, and patents. He previously worked at the Federal Trade Commission's Bureau of Economics. He had also taught marketing and consumer behavior at the business schools of the University of Maryland at College Park and Boston University. While Mr. Calfee's writings are mostly on pharmaceutical markets and FDA regulation, his academic articles and opinion pieces covered a variety of topics, from patent law and tort liability to advertising and consumer information. His books include Prices, Markets, and the Pharmaceutical Revolution (AEI Press, 2000) and Biotechnology and the Patent System (AEI Press, 2007). Mr. Calfee wrote regularly for AEI's Health Policy Outlook series. He testified before Congress and federal agencies on various topics, including alcohol advertising; biodefense vaccine research; international drug prices; and FDA oversight of drug safety.

 

Tomas J.
Philipson
AEI on Facebook